Intra-Cellular Therapies Inc (NASDAQ: ITCI) is 0.53% higher on its value in year-to-date trading and has touched a low of $45.50 and a high of $84.89 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ITCI stock was last observed hovering at around $76.69 in the last trading session, with the day’s loss setting it -4.69%.
Currently trading at $72.00, the stock is 4.69% and 4.07% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.71 million and changing -6.12% at the moment leaves the stock 16.28% off its SMA200. ITCI registered 15.40% gain for a year compared to 6-month gain of 34.43%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 10.01% loss in the last 1 month and extending the period to 3 months gives it a 10.53%, and is 5.93% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.26% over the week and 3.98% over the month.
Intra-Cellular Therapies Inc (ITCI) has around 610 employees, a market worth around $6.97B and $464.37M in sales. Fwd P/E is 67.89. Profit margin for the company is -30.08%. Distance from 52-week low is 58.24% and -15.18% from its 52-week high. The company has generated returns on investments over the last 12 months (-23.10%).
The EPS is expected to grow by 52.43% this year
The shares outstanding are 96.38M, and float is at 94.22M with Short Float at 3.68%.
Intra-Cellular Therapies Inc (ITCI) Insider Activity
The most recent transaction is an insider sale by Mates Sharon, the company’s Chairman, President & CEO. SEC filings show that Mates Sharon sold 20,565 shares of the company’s common stock on Mar 11 ’24 at a price of $65.21 per share for a total of $1.34 million. Following the sale, the insider now owns 1.05 million shares.
Intra-Cellular Therapies Inc disclosed in a document filed with the SEC on Mar 11 ’24 that Hineline Lawrence J. (SVP of Finance, CFO) sold a total of 10,121 shares of the company’s common stock. The trade occurred on Mar 11 ’24 and was made at $65.96 per share for $0.67 million. Following the transaction, the insider now directly holds 0.0 shares of the ITCI stock.
Still, SEC filings show that on Mar 11 ’24, Halstead Michael (EVP and General Counsel) disposed off 7,345 shares at an average price of $65.97 for $0.48 million. The insider now directly holds 0 shares of Intra-Cellular Therapies Inc (ITCI).
